Our venture capital fund focuses investments on early-stage life sciences companies looking to improve people’s outcomes with cancer.

Recent News

C4-logo-400
01/30/2023

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors

READ MORE
Logo-Geneoscopy-Full
01/24/2023

Geneoscopy Submits Premarket Approval Application to FDA for its Noninvasive Colorectal Cancer RNA Biomarker Screening Test

READ MORE
wugen-logo-400
01/21/2023

Wugen Presents Data on WU-NK-101 in Combination with Cetuximab in Preclinical Models of Advanced Colorectal Cancer (CRC) at ASCO Gastrointestinal Cancers Symposium

READ MORE
Logo-Geneoscopy-400
01/10/2023

Geneoscopy’s Noninvasive Colorectal Cancer Screening Test Demonstrates High Sensitivity and Specificity in Large Pivotal Clinical Trial

READ MORE
C4-logo-400
01/09/2023

C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines

READ MORE
C4-logo-400
01/03/2023

C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

READ MORE
aiProteins_Final_logo300
12/14/2022

AI Proteins Expands Executive Team with Hire of Industry Veteran Wendy Dwyer as Chief Business Officer

READ MORE
Logo-Geneoscopy-400
12/13/2022

Geneoscopy Receives Accreditation from the College of American Pathologists (CAP) for its St. Louis Clinical Laboratory

READ MORE
Logo-Geneoscopy-400
12/13/2022

Geneoscopy Receives Accreditation from the College of American Pathologists (CAP) for its St. Louis Clinical Laboratory

READ MORE

PORTFOLIO HIGHLIGHTS

WUGEN Logo
White C4 Therapeutics logo
Geneoscopy logo
NextRNA Logo
CareVet Logo
microbial-logo-header300